Abstract
Background
The bridging integrator 1 (BIN1) protein was originally identified as a pro-apoptotic tumor suppressor that binds to and inhibits oncogenic MYC transcription factors. BIN1 has complex physiological functions participating in endocytosis, membrane cycling, cytoskeletal regulation, DNA repair deficiency, cell-cycle arrest, and apoptosis. The expression of BIN1 is closely related to the development of various diseases such as cancer, Alzheimer's disease, myopathy, heart failure, and inflammation.
Purpose
Because BIN1 is commonly expressed in terminally differentiated normal tissues and is usually undetectable in refractory or metastatic cancer tissues, this differential expression has led us to focus on human cancers associated with BIN1. In this review, we discuss the potential pathological mechanisms of BIN1 during cancer development and its feasibility as a prognostic marker and therapeutic target for related diseases based on recent findings on its molecular, cellular, and physiological roles.
Conclusion
BIN1 is a tumor suppressor that regulates cancer development through a series of signals in tumor progression and microenvironment. It also makes BIN1 a feasible early diagnostic or prognostic marker for cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data sharing not applicable to this article as no data was generated or analysed during the current study.
References
Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502–516. https://doi.org/10.1038/nrc1123
Ahel I, Ahel D, Matsusaka T et al (2008) Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451:81–85. https://doi.org/10.1038/nature06420
Ahmadzada T, Lee K, Clarke C et al (2019) High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer 130:35–41. https://doi.org/10.1016/j.lungcan.2019.02.005
Akbay EA, Koyama S, Carretero J et al (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3:1355–1363. https://doi.org/10.1158/2159-8290.CD-13-0310
Anczukow O, Rosenberg AZ, Akerman M et al (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19:220–228. https://doi.org/10.1038/nsmb.2207
Azuma K, Ota K, Kawahara A et al (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25:1935–1940. https://doi.org/10.1093/annonc/mdu242
Baban B, Hansen AM, Chandler PR et al (2005) A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 17:909–919. https://doi.org/10.1093/intimm/dxh271
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302. https://doi.org/10.1093/jnci/92.16.1295
Bretscher PA (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 96:185–190. https://doi.org/10.1073/pnas.96.1.185
Brown JS, Kaye SB, Yap TA (2016) PARP inhibitors: the race is on. Br J Cancer 114:713–715. https://doi.org/10.1038/bjc.2016.67
Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917. https://doi.org/10.1038/nature03443
Butler MH, David C, Ochoa GC et al (1997) Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of ranvier in brain and around T tubules in skeletal muscle. J Cell Biol 137:1355–1367. https://doi.org/10.1083/jcb.137.6.1355
Casey SC, Tong L, Li Y et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227–231. https://doi.org/10.1126/science.aac9935
Cassimere EK, Pyndiah S, Sakamuro D (2009) The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ 16:1641–1653. https://doi.org/10.1038/cdd.2009.98
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76:359–370. https://doi.org/10.1016/j.molcel.2019.09.030
Chang MY, Boulden J, Katz JB et al (2007a) Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 67:7605–7612. https://doi.org/10.1158/0008-5472.CAN-07-1100
Chang MY, Boulden J, Sutanto-Ward E et al (2007b) Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 67:100–107. https://doi.org/10.1158/0008-5472.CAN-06-2742
Chen N, Fang W, Zhan J et al (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 10:910–923. https://doi.org/10.1097/JTO.0000000000000500
Concha-Benavente F, Srivastava RM, Trivedi S et al (2016) Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Cancer Res 76:1031–1043. https://doi.org/10.1158/0008-5472.CAN-15-2001
Curiel TJ, Wei S, Dong H et al (2003) Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562–567. https://doi.org/10.1038/nm863
Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512–1517. https://doi.org/10.1093/jnci/84.19.1512
Das S, Anczuków O, Akerman M, Krainer AR (2012) Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1:110–117. https://doi.org/10.1016/j.celrep.2011.12.001
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110. https://doi.org/10.1038/nrc3447
Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48:6058–6062
Drager NM, Nachman E, Winterhoff M et al (2017) Bin1 directly remodels actin dynamics through its BAR domain. EMBO Rep 18:2051–2066. https://doi.org/10.15252/embr.201744137
DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC (2001) Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res 61:3151–3156
DuHadaway JB, Du W, Donover S et al (2003a) Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene 22:3578–3588. https://doi.org/10.1038/sj.onc.1206481
DuHadaway JB, Lynch FJ, Brisbay S et al (2003b) Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 88:635–642. https://doi.org/10.1002/jcb.10380
Elliott K, Sakamuro D, Basu A et al (1999) Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 18:3564–3573. https://doi.org/10.1038/sj.onc.1202670
Elliott K, Ge K, Du W, Prendergast GC (2000) The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 19:4669–4684. https://doi.org/10.1038/sj.onc.1203681
Eperon IC, Makarova OV, Mayeda A et al (2000) Selection of alternative 5’ splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol Cell Biol 20:8303–8318. https://doi.org/10.1128/MCB.20.22.8303-8318.2000
Esmailzadeh S, Huang Y, Su MW, Zhou Y, Jiang X (2015) BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia 29:1402–1413. https://doi.org/10.1038/leu.2015.9
Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03445
Folk WP, Kumari A, Iwasaki T et al (2019) Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. J Biol Chem 294:5700–5719. https://doi.org/10.1074/jbc.RA118.005699
Folk WP, Kumari A, Iwasaki T et al (2021) New synthetic lethality re-sensitizing platinum-refractory cancer cells to cisplatin in vitro: The rationale to Co-Use PARP and ATM inhibitors. Int J Mol Sci 22. https://doi.org/10.3390/ijms222413324
Galderisi U, Di Bernardo G, Cipollaro M et al (1999) Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J Cell Biochem 74:313–322
Ganesan S (2011) MYC, PARP1, and chemoresistance: BIN there, done that? Sci Signal. https://doi.org/10.1126/scisignal.2001946
Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC (1999) Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A 96:9689–9694. https://doi.org/10.1073/pnas.96.17.9689
Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC (2000a) Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 85:376–383
Ge K, Minhas F, Duhadaway J et al (2000b) Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 86:155–161. https://doi.org/10.1002/(sici)1097-0215(20000415)86:2%3c155::aid-ijc2%3e3.0.co;2-m
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6:8. https://doi.org/10.1186/s40425-018-0316-z
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176–1178. https://doi.org/10.4161/cc.4.9.2031
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193–204. https://doi.org/10.1038/nrc2342
Hogarty MD, Liu X, Thompson PM et al (2000) BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Med Pediatr Oncol 35:559–562. https://doi.org/10.1002/1096-911x(20001201)35:6%3c559::aid-mpo14%3e3.0.co;2-j
Hong TT, Cogswell R, James CA et al (2012a) Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 9:961–967. https://doi.org/10.1016/j.hrthm.2012.01.024
Hong TT, Smyth JW, Chu KY et al (2012b) BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. Heart Rhythm 9:812–820. https://doi.org/10.1016/j.hrthm.2011.11.055
Hong T, Yang H, Zhang SS et al (2014) Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia. Nat Med 20:624–632. https://doi.org/10.1038/nm.3543
Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596–3599. https://doi.org/10.4049/jimmunol.164.7.3596
Iversen TZ, Engell-Noerregaard L, Ellebaek E et al (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20:221–232. https://doi.org/10.1158/1078-0432.CCR-13-1560
Ji Y, Tulin AV (2010) The roles of PARP1 in gene control and cell differentiation. Curr Opin Genet Dev 20:512–518. https://doi.org/10.1016/j.gde.2010.06.001
Jia Y, Wang H, Wang Y et al (2015) Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 137:1095–1106. https://doi.org/10.1002/ijc.29481
Kerbel RS, Kobayashi H, Graham CH (1994) Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56:37–47. https://doi.org/10.1002/jcb.240560108
Kim KC, Kim TS, Kang KH, Choi KH (2001) Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73beta function through protein-protein interactions. Oncogene 20:6689–6699. https://doi.org/10.1038/sj.onc.1204839
Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D (2008) Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. J Cell Physiol 216:621–631. https://doi.org/10.1002/jcp.21437
Konecny GE, Kristeleit RS (2016) PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 115:1157–1173. https://doi.org/10.1038/bjc.2016.311
Kraus WL (2008) Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 20:294–302. https://doi.org/10.1016/j.ceb.2008.03.006
Kumari A, Iwasaki T, Pyndiah S, Cassimere EK, Palani CD, Sakamuro D (2015) Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation. Cell Death Differ 22:311–322. https://doi.org/10.1038/cdd.2014.146
Kumari A, Folk WP, Sakamuro D (2017) The dual roles of MYC in genomic instability and cancer chemoresistance. Genes (basel). https://doi.org/10.3390/genes8060158
Lambert AW, Weinberg RA (2021) Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer 21:325–338. https://doi.org/10.1038/s41568-021-00332-6
Lee E, Marcucci M, Daniell L et al (2002) Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. Science 297:1193–1196. https://doi.org/10.1126/science.1071362
Leonetti C, Biroccio A, Candiloro A et al (1999) Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 5:2588–2595
Li MX, Wang HY, Yuan CH et al (2021) Establishment of a macrophage phenotypic switch related prognostic signature in patients with pancreatic cancer. Front Oncol 11:619517. https://doi.org/10.3389/fonc.2021.619517
Lin JC (2017) Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment. Int J Mol Sci. https://doi.org/10.3390/ijms19010075
Lin H, Wei S, Hurt EM et al (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128:805–815. https://doi.org/10.1172/JCI96113
Lob S, Konigsrainer A, Zieker D et al (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58:153–157. https://doi.org/10.1007/s00262-008-0513-6
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292. https://doi.org/10.1002/path.1706
Loret N, Denys H, Tummers P, Berx G (2019) The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers (basel). https://doi.org/10.3390/cancers11060838
Lundgaard GL, Daniels NE, Pyndiah S et al (2011) Identification of a novel effector domain of BIN1 for cancer suppression. J Cell Biochem 112:2992–3001. https://doi.org/10.1002/jcb.23222
Lv W, Jia Y, Wang J et al (2022) Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p. Cell Death Discov 8:60. https://doi.org/10.1038/s41420-022-00825-9
Mao NC, Steingrimsson E, DuHadaway J et al (1999) The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2. Genomics 56:51–58. https://doi.org/10.1006/geno.1998.5709
McKenna ES, Tamayo P, Cho YJ et al (2012) Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle 11:1956–1965. https://doi.org/10.4161/cc.20280
Mellor AL, Munn DH (2011) Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol 186:4535–4540. https://doi.org/10.4049/jimmunol.1002937
Mellor AL, Baban B, Chandler P et al (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171:1652–1655. https://doi.org/10.4049/jimmunol.171.4.1652
Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA (2008) Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 117:81–90. https://doi.org/10.1016/j.imlet.2007.12.013
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312–319. https://doi.org/10.1038/nm1196
Munn DH, Sharma MD, Lee JR et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870. https://doi.org/10.1126/science.1073514
Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D (1996) The Bin1 gene localizes to human chromosome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization. Genomics 33:329–331. https://doi.org/10.1006/geno.1996.0205
Nicot AS, Toussaint A, Tosch V et al (2007) Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 39:1134–1139. https://doi.org/10.1038/ng2086
Oei SL, Keil C, Ziegler M (2005) Poly(ADP-ribosylation) and genomic stability. Biochem Cell Biol 83:263–269. https://doi.org/10.1139/o05-039
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33. https://doi.org/10.1016/j.molmed.2014.10.009
Perego P, Giarola M, Righetti SC et al (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556–562
Pineda-Lucena A, Ho CS, Mao DY et al (2005) A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 351:182–194. https://doi.org/10.1016/j.jmb.2005.05.046
Prendergast GC (2000) Mode of action of farnesyltransferase inhibitors. Lancet Oncol 1:73. https://doi.org/10.1016/s1470-2045(00)00073-5
Prendergast GC, Muller AJ, Ramalingam A, Chang MY (2009) BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta 1795:25–36. https://doi.org/10.1016/j.bbcan.2008.09.001
Prokic I, Cowling BS, Laporte J (2014) Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (berl) 92:453–463. https://doi.org/10.1007/s00109-014-1138-1
Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D (2011) c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 4:ra19. https://doi.org/10.1126/scisignal.2001556
Pyndiah S, Sakamuro D (2013) c-MYC, PARP1 and BIN1 as targets for therapy of cancer cell resistance. Med Sci (paris) 29:133–135. https://doi.org/10.1051/medsci/2013292006
Radpour R, Barekati Z, Kohler C et al (2011) Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 6:e16080. https://doi.org/10.1371/journal.pone.0016080
Ragaini S, Wagner S, Marconi G et al (2022) An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. Blood Adv 6:87–99. https://doi.org/10.1182/bloodadvances.2021004878
Ramalingam A, Prendergast GC (2007) Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle 6:1655–1662. https://doi.org/10.4161/cc.6.13.4413
Ramjaun AR, Micheva KD, Bouchelet I, McPherson PS (1997) Identification and characterization of a nerve terminal-enriched amphiphysin isoform. J Biol Chem 272:16700–16706. https://doi.org/10.1074/jbc.272.26.16700
Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC (1996) BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 14:69–77. https://doi.org/10.1038/ng0996-69
Sakamuro D, Folk WP, Kumari A (2015) To die, or not to die: E2F1 never decides by itself during serum starvation. Mol Cell Oncol 2:e981447. https://doi.org/10.4161/23723556.2014.981447
Sanmamed MF, Chen L (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313–326. https://doi.org/10.1016/j.cell.2018.09.035
Sharma MD, Baban B, Chandler P et al (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117:2570–2582. https://doi.org/10.1172/JCI31911
Sharma MD, Hou DY, Liu Y et al (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102–6111. https://doi.org/10.1182/blood-2008-12-195354
Sheridan E, Silcocks P, Smith J, Hancock BW, Goyns MH (1994) P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer 30A:1701–1704. https://doi.org/10.1016/0959-8049(94)00325-y
Shultz JC, Goehe RW, Murudkar CS et al (2011) SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 9:889–900. https://doi.org/10.1158/1541-7786.MCR-11-0061
Sun C, Mezzadra R, Schumacher TN (2018) Regulation and Function of the PD-L1 Checkpoint. Immunity 48:434–452. https://doi.org/10.1016/j.immuni.2018.03.014
Tajiri T, Liu X, Thompson PM et al (2003) Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 9:3345–3355
Tan MS, Yu JT, Tan L (2013) Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol Med 19:594–603. https://doi.org/10.1016/j.molmed.2013.06.004
Tang H, Liang Y, Anders RA et al (2018) PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest 128:580–588. https://doi.org/10.1172/JCI96061
Terme M, Pernot S, Marcheteau E et al (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539–549. https://doi.org/10.1158/0008-5472.CAN-12-2325
Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7–H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101:17174–17179. https://doi.org/10.1073/pnas.0406351101
Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461. https://doi.org/10.1016/j.ccell.2015.03.001
Tsutsui K, Maeda Y, Tsutsui K, Seki S, Tokunaga A (1997) cDNA cloning of a novel amphiphysin isoform and tissue-specific expression of its multiple splice variants. Biochem Biophys Res Commun 236:178–183. https://doi.org/10.1006/bbrc.1997.6927
Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274. https://doi.org/10.1038/nm934
Vacchelli E, Aranda F, Eggermont A et al (2014) Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 3:e957994. https://doi.org/10.4161/21624011.2014.957994
Wang J, Jia Y, Zhao S et al (2017a) BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene 36:6235–6243. https://doi.org/10.1038/onc.2017.217
Wang X, Wang J, Jia Y et al (2017b) Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition. Oncotarget 8:19661–19673. https://doi.org/10.18632/oncotarget.14914
Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC (1997a) The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res 57:3258–3263
Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC (1997b) Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem 272:31453–31458. https://doi.org/10.1074/jbc.272.50.31453
Wechsler-Reya RJ, Elliott KJ, Prendergast GC (1998) A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol 18:566–575. https://doi.org/10.1128/MCB.18.1.566
Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J (2015) Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev:CD007929. https://doi.org/10.1002/14651858.CD007929.pub3
Woodhouse BC, Dianov GL (2008) Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair (amst) 7:1077–1086. https://doi.org/10.1016/j.dnarep.2008.03.009
Zhang B, Zelhof AC (2002) Amphiphysins: raising the BAR for synaptic vesicle recycling and membrane dynamics. Bin-Amphiphysin-Rvsp Traffic 3:452–460. https://doi.org/10.1034/j.1600-0854.2002.30702.x
Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv324. https://doi.org/10.1126/scitranslmed.aad7118
Funding
This work was supported by the regulatory mechanism of AMPK in ischemic-reperfusion injury and fibrosis in renal transplantation (CY2015-YJRC08); Gansu Provincial Education Department outstanding graduate “innovation star” project (2021CXZX-154); the Open Foundation of Gansu Key Laboratory of Functional Genomics and Molecular Diagnostics; Gansu Province Intellectual Property Planning project (21ZSCQ012); the Second Hospital of Lanzhou University "Cuiying Science and Technology Innovation" project (CY2021-QN-A20).
Author information
Authors and Affiliations
Contributions
CS: protocol development, data collection and management, data analysis and manuscript writing. CJ: protocol development, data collection and management, data analysis and manuscript writing. LK: protocol development, data collection and management, and manuscript writing. WS: protocol development, data collection and management, and manuscript writing. YL: protocol development, data management and manuscript writing.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests. The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, Sy., Cao, Jl., Li, Kp. et al. BIN1 in cancer: biomarker and therapeutic target. J Cancer Res Clin Oncol 149, 7933–7944 (2023). https://doi.org/10.1007/s00432-023-04673-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-04673-7